Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 10, 2005. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of share transactions rather than a financial performance report.
Material Changes
The material change reported is a transfer of 111,669 Ordinary Shares from the GlaxoSmithKline Employee Trust ("the GSK Trust") to participants in the SmithKline Beecham Employee Share Option Plan 1991. This transaction occurred on November 8, 2005, and the Company was advised of it on November 9, 2005.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly details a transaction notified in accordance with Disclosure Rule 3.1.4R(1)(b). The GSK Trust is identified as a discretionary trust where all current and former employees are potential beneficiaries.
Investor Verification Points
- Verify the impact of the 111,669 share transfer on the total outstanding share count.
- Confirm the specific allocation of shares among participants in the SmithKline Beecham Employee Share Option Plan 1991.
- Note that Directors Dr J-P Garnier, Dr T Yamada, and Mr J S Heslop hold interests in the GSK Trust shares similarly to other employees.
- Check subsequent filings for any financial performance data, as this 6-K does not contain earnings or balance sheet information.